Active tumor targeting of nanomaterials using folic acid, transferrin and integrin receptors

Area of Science:

• Oncology
• Nanotechnology
• Biochemistry

Background:

• Folic acid, transferrin, and integrin alpha v beta 3 (αvβ3) receptors are frequently overexpressed on cancer cells.
• Ligands targeting these overexpressed receptors are crucial for concentrating therapeutic agents at tumor sites.
• Nanocarriers are essential for delivering therapeutic agents effectively.

Purpose of the Study:

• To review the application of specific ligands for targeted drug delivery using nanocarriers.
• To analyze nanocarrier systems optimized for both in vitro binding and in vivo pharmacokinetics.
• To understand the key factors that influence the targeting efficacy of nanocarriers.

Main Methods:

• Review of scientific literature on ligand-targeted nanocarriers.
• Analysis of drug delivery systems including liposomes, dendrimers, and N-(2-hydroxypropyl) methacrylamide (HPMA) copolymers.
• Evaluation of in vitro binding assays and in vivo pharmacokinetic studies.

Main Results:

• Ligand-nanocarrier conjugates demonstrate enhanced tumor localization.
• Optimized nanocarriers show improved in vitro binding affinities.
• In vivo studies highlight the impact of nanocarrier design on pharmacokinetic profiles.

Conclusions:

• Ligand-targeted nanocarriers offer a promising strategy for cancer therapy.
• Further optimization of nanocarrier systems is needed to maximize targeting efficiency.
• Understanding factors influencing nanocarrier targeting is key for successful clinical translation.